...Oscient Pharmaceuticals Corp. , which has been dissolved. Oscient had U.S. rights to Antara from Reliant Pharmaceuticals Inc....

...build more than a product launch," he added. A successful market build, Miller noted, was Reliant Pharmaceuticals Inc....

...in 2007 was primarily due to the inclusion of the $1.7 billion takeout of venture-backed Reliant Pharmaceuticals Inc....

...NASDAQ:AMRN), Dublin, Ireland Business: Cardiovascular Hired: Paul Huff as CCO, formerly VP of marketing at Reliant Pharmaceuticals Inc. WIR...

...increased triglycerides. Pronova Biopharma ASA licensed the U.S. rights to the fish oil formulation to Reliant Pharmaceuticals...

...Lovaza eicosapentaenoic acid/docosanexaenoic acid. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), which obtained Lovaza through its acquisition of Reliant Pharmaceuticals Inc....

...a lipid-lowering agent to treat hypercholesterolemia and hypertriglyceridemia. Oscient has U.S. rights to Antara from Reliant Pharmaceuticals Inc....

...Oscient has U.S. rights to Antara, a lipid-lowering agent to treat hypercholesterolemia and hypertriglyceridemia, from Reliant Pharmaceuticals Inc....

...and a nine-month operating loss of $29.5 million. Oscient has U.S. rights to Antara from Reliant Pharmaceuticals Inc....

...FDA for a generic version of fenofibrate. Oscient acquired U.S. marketing rights to Antara from Reliant Pharmaceuticals Inc....